Basal cell carcinoma (BCC) · line 1 · Sonidegib monotherapy (locally advanced BCC)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	aggressive
Linked regimen	`REG-SONIDEGIB-BCC`

ID	`IND-BCC-1L-SONIDEGIB`
Type	Indication
Status	reviewed 2026-05-04 \| pending_clinical_signoff
Diseases	`DIS-BCC`
Sources	`SRC-NCCN-SKIN-2025`

Notes

STUB — pending Clinical Co-Lead sign-off. Aggressive-track HHI alternative for laBCC (not mBCC). BOLT 200 mg arm has strong laBCC ORR data. Key restriction: laBCC only per FDA label.

Used By

Algorithms

ALGO-BCC-1L - ALGO-BCC-1L